Table 2.
Characteristics of cholestatic liver disease-diagnosed patients with serum samples.
All patients n = 205 |
Early disease n = 152 |
Advanced disease n = 53 |
p value∗ | |
---|---|---|---|---|
Sex (F/M) | 155/50 | 116/36 | 39/14 | 0.69 |
Aetiology (PBC/PSC) | 147/58 | 108/44 | 39/14 | 0.72 |
Age (years) | 51.4 ± 15.3 | 50.9 ± 15.6 | 53.0 ± 14.3 | 0.40 |
AMA+ (%) | 55.5 | 56.4 | 52.9 | 0.67 |
ANA+ (%) | 37.2 | 33.1 | 49.0 | 0.04 |
IgM (mg/dl) | 238.8 ± 157.4 | 224.1 ± 159.2 | 281.4 ± 144.4 | <0.01 |
AST (U/L) | 52.2 ± 67.0 | 45.6 ± 71.4 | 70.4 ± 48.9 | <0.01 |
ALP (U/L) | 190.5 ± 161.4 | 171.6 ± 132.0 | 244.8 ± 218.1 | <0.01 |
tBIL (mg/dl) | 1.3 ± 2.1 | 1.0 ± 1.6 | 2.3 ± 2.8 | <0.01 |
Albumin (g/dl) | 4.2 ± 0.6 | 4.4 ± 0.4 | 3.7 ± 0.7 | <0.01 |
Platelet (109/L) | 210.8 ± 88.0 | 246.0 ± 58.8 | 109.7 ± 79.7 | <0.01 |
LSM by VCTE (kPa) | 8.5 ± 7.9 | 5.7 ± 1.6 | 20.8 ± 11.8 | <0.01 |
APRI | 0.9 ± 1.4 | 0.5 ± 0.8 | 2.2 ± 1.7 | <0.01 |
Inadequate response to UDCA (%)# | 50.2 | 39.5 | 81.1 | <0.01 |
Anti-MCJ Ab (%) | 17.1 | 15.8 | 20.8 | 0.41 |
#Biochemical response to UDCA was assessed using Paris-II criteria. Data are expressed as mean ± SD. ∗Early disease vs. advanced disease (Chi-square or Student t or Mann-Whitney U test). Bold values denote statistical significance. Ab, antibody; ALP, alkaline phosphatases; AMA, antimitochondrial antibodies; ANA, antinuclear antibodies; APRI, AST to platelet ratio index; AST, aspartate aminotransferase; LSM, liver stiffness; tBIL, total bilirubin; UDCA, ursodeoxycholic acid; VCTE, vibration-controlled transient elastography.